{"id":279,"date":"2015-03-31T19:43:04","date_gmt":"2015-03-31T19:43:04","guid":{"rendered":"http:\/\/apogee-biotech.com\/?p=279"},"modified":"2020-05-19T14:32:10","modified_gmt":"2020-05-19T14:32:10","slug":"apogee-licenses-abc294640-to-redhill-biopharma-march-31","status":"publish","type":"post","link":"http:\/\/apogee-biotech.com\/index.php\/apogee-licenses-abc294640-to-redhill-biopharma-march-31\/","title":{"rendered":"Apogee Licenses ABC294640 to RedHill Biopharma"},"content":{"rendered":"<p>Apogee has successfully licensed exclusive rights to ABC294640 to RedHill Biopharma.&nbsp; Apogee looks forward to working closely with RedHill for late stage clinical development in many cancer and inflammatory indications.<\/p>\n<p><a href=\"http:\/\/globenewswire.com\/news-release\/2015\/03\/31\/720531\/10126995\/en\/RedHill-Biopharma-Acquires-Phase-II-First-in-Class-Oral-Small-Molecule-SK2-Inhibitor-From-Apogee-Biotech.html\">http:\/\/globenewswire.com\/news-release\/2015\/03\/31\/720531\/10126995\/en\/RedHill-Biopharma-Acquires-Phase-II-First-in-Class-Oral-Small-Molecule-SK2-Inhibitor-From-Apogee-Biotech.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Apogee has successfully licensed exclusive rights to ABC294640 to RedHill Biopharma.&nbsp; Apogee looks forward to working closely with RedHill for late stage clinical development in many cancer and inflammatory indications. http:\/\/globenewswire.com\/news-release\/2015\/03\/31\/720531\/10126995\/en\/RedHill-Biopharma-Acquires-Phase-II-First-in-Class-Oral-Small-Molecule-SK2-Inhibitor-From-Apogee-Biotech.html<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[1],"tags":[],"_links":{"self":[{"href":"http:\/\/apogee-biotech.com\/index.php\/wp-json\/wp\/v2\/posts\/279"}],"collection":[{"href":"http:\/\/apogee-biotech.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/apogee-biotech.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/apogee-biotech.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/apogee-biotech.com\/index.php\/wp-json\/wp\/v2\/comments?post=279"}],"version-history":[{"count":12,"href":"http:\/\/apogee-biotech.com\/index.php\/wp-json\/wp\/v2\/posts\/279\/revisions"}],"predecessor-version":[{"id":352,"href":"http:\/\/apogee-biotech.com\/index.php\/wp-json\/wp\/v2\/posts\/279\/revisions\/352"}],"wp:attachment":[{"href":"http:\/\/apogee-biotech.com\/index.php\/wp-json\/wp\/v2\/media?parent=279"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/apogee-biotech.com\/index.php\/wp-json\/wp\/v2\/categories?post=279"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/apogee-biotech.com\/index.php\/wp-json\/wp\/v2\/tags?post=279"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}